NCT01066364View on ClinicalTrials.gov

Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis

PHASE2CompletedINTERVENTIONAL

Enrollment

59

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions

Nonalcoholic Steatohepatitis

Interventions

DRUG

Colesevelam Hcl

3.75 gm/day (six 675 mg tablets)

Trial Locations (2)

92093

UCSD: Prevention Studies Clinic, La Jolla

92103

UCSD: Medical Center- Hillcrest, San Diego

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Daiichi Sankyo

INDUSTRY

lead

University of California, San Diego

OTHER

NCT01066364 - Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis | Biotech Hunter | Biotech Hunter